Sol-Gel Technologies (SLGL) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Sol-Gel Technologies (SLGL) develops biotechnological solutions for dermatology, utilizing a method of encapsulating active components in silica spheres to combat rosacea and acne. The company's revenues rely on royalty payments, as external partners handle distribution. This price chart, which assists in the basic valuation of the asset, demonstrates an EV/EBITDA ratio of 0.00. High efficacy and minimal side effects allow the brand to maintain its position in the premium pricing segment.

Sol-Gel Technologies (SLGL) is developing an innovative portfolio of dermatology products based on microencapsulation, which requires precise control of capital expenditures. On the GURU.Markets platform, the EV/EBITDA metric, accounting for debt and amortization, compares the total enterprise value with operating profit before taxes, allowing investors to assess the real value of assets relative to their ability to generate cash flow during the clinical testing period.